Podcasts about zepbound

It's in the News! The top diabetes stories and headlines happening now. Top stories this week include: Afrezza inhaled Insulin is Approved for Kids, CGM + Ketone Monitor gets European approval, Food Coloring & Diabetes Study, Device Recalls include Omnipod and Dexcom, Beta Bionics shares more about their patch pump, ADA conference info and more! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcripts: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. ADA starts this week – safe travels to those of you heading to New Orleans. We'll be covering remotely so please follow on social – make sure to Like the FB page or join the group. We've got a wrap up episode planned for this podcast as well as some indepth interviews with the newsmakers from the conference. I will see some of you next week in Chicago. We have a couple of seats left for our Club 1921 dinner on June 10th in Northbrook – this is a FREE dinner for HCPs and patient leaders – all about screening for T1D. More info on the website under the events tab. Okay.. our top story this week: XX Afrezza inhaled insulin is now approved for kids and teens. The FDA okayed MannKind's afrezza for children 6 and older with type 1 and type 2 diabetes. MannKind says its proprietary Technosphere drug delivery platform enables the rapid absorption of insulin into systemic circulation. This follows FDA approval earlier this year for an update that revises recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. MannKind also completed enrollment in February for a study evaluating the initiation of Afrezza therapy shortly after type 1 diabetes diagnosis in pediatric patients.   The company said it made Afrezza available for eligible patients for $35 or less per month. Desmond Schatz, professor of pediatrics at the University of Florida College of Medicine, said: "Mealtime insulin can be especially challenging for children because eating and snacking patterns, activity levels, and daily settings like school and sports often vary. With its rapid onset and dosing at the start of a meal, Afrezza may help clinicians better match insulin therapy to how children and families live day to day, while offering a needle-free mealtime option." Lots more to come on this – we're working on a bonus episode with one of the pediatric endos who worked on the clinical trials that led to this approval – hopefully have that out later this week. https://www.massdevice.com/mannkind-fda-approval-inhaled-insulin-children/ XX FDA has agreed to consider a new drug for the treatment of adults with type 1 and chronic kidney disease. Finerenone (fy-near-uh-known) is currently approved in the US for adults with CKD associated with type 2 diabetes and for adults with heart failure with left ventricular ejection fraction of 40% or greater. Chronic kidney disease (CKD) is present in over one-third of adults with diabetes, and because it's such a serious condition, interventions are needed to reduce its incidence and help people live a long and prosperous life. https://www.docwirenews.com/post/fda-grants-priority-review-to-finerenone-snda-for-type-1-diabetes-associated-ckd XX Abbot gets European approval for the world's first dual glucose‑ketone sensing technology for people with diabetes. They're calling this Libre Duo and Libre Duo 10 Day, and it's designed to continuously measure glucose and ketone levels every minute. Abbott plans to begin launching Libre Duo systems in select European countries later this year. Libre Duo delivers up to 15 days of wear and will be offered to adults ages 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people ages 2 and older. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors. https://abbott.mediaroom.com/2026-05-27-Abbott-secures-CE-Mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes   XX Huge recall for Omnipod. Insulin says a manufacturing issue through ongoing product monitoring that could result in insulin under-delivery  with specific lots of its Omnipod 5, Dash and Eros pods. Insulet said the scope of this action reaches approximately 7 million pods. This issue is separate from the March recall that affected certain Omnipod 5 lots. According to the Acton, Massachusetts-based company, some of its affected pods may have a small tear in the tubing (cannula) just above the skin. This tear lands between the pod and the point where the cannula enters the body. If this occurs, insulin may leak outside of the device instead of being fully delivered into the body as intended. This may lead to under-delivery of the therapeutic.   Individuals using an affected pod may notice wetness on the skin or pod adhesive or detect the smell of insulin. However, some cases may prove difficult to detect and go unnoticed. Of the approximately 7 million pods included in the action, approximately 60% have been consumed or are expired. The pods affected by the correction represent approximately 8.5% of the 2025 global Omnipod pod prodcution. Insulet says it has sufficient supply to replace affected pods. It expects no disruption to product availability. The company said it has notified the FDA and all other relevant regulatory authorities of its action.   The full list of affected pod lots can be found here. https://www.massdevice.com/insulet-another-omnipod-5-recall-dash-eros/ XX Dexcom is warning that certain scrapped glucose sensors have been stolen and resold. Dexcom said it has not received any reports of severe adverse events associated with the stolen product. One lot of scrapped devices carries a risk of infection for sensors that are not properly sterilized, and another lot had an elevated internal testing failure rate, meaning users would have an increased risk of having no sensor readings available. Dexcom said the affected sensors were stolen during the destruction process and then sold by third parties. The company routinely scraps sensors that do not meet its standards. The sensors are sent to a third-party vendor for destruction and recycling.   Dexcom said it traced sales of the stolen devices to Pharmsource, which is not an authorized Dexcom distributor but supplies some independent pharmacies and U.S. durable medical equipment distributors. Because of this, pharmacies that purchase products from Pharmsource should review their inventory, Dexcom said.   People with sensors from the affected lots should not use those sensors and can call customer support to request replacements. Dexcom has set up a website to help users check if their devices are affected. https://www.medtechdive.com/news/dexcom-warns-of-scrapped-glucose-sensors-being-resold/821139/ XX XX   Beta Bionics plans to debut its first insulin patch pump by the end of the second quarter of 2027, subject to Food and Drug Administration clearance. The device, called Mint, would be compatible with Beta Bionics' interoperable automated glycemic controller, a software that allows for the pump to automatically adjust insulin delivery based on readings from a glucose sensor. Beta Bionics first unveiled the prototype for Mint last year at the American Diabetes Association's Scientific Sessions. The device is expected to have a similar size and wear time, at three days, to Insulet's patch pumps on the market. It would have a 200-unit insulin reservoir.   Mint differs by containing a mix of reusable and disposable components. Beta Bionics plans to make the device exclusively available in the pharmacy channel, building on its existing agreements for its current iLet insulin pump. Beta Bionics is one of several diabetes tech companies developing patch pumps to compete with market leader Insulet. Tandem Diabetes Care and Medtronic spinoff MiniMed have also announced planned patch pumps. Tandem said it plans to file a 510(k) submission this quarter for a tubeless version of its small, durable pump, and Medtronic plans to submit its patch pump to the FDA this fall.   https://www.medtechdive.com/news/beta-bionics-to-launch-its-first-insulin-patch-pump-to-compete-with-insulet/821091/ XX CVS puts Zepbound back on it's coverage list – with it's Caremark PBM. They also added Foundayo, Lilly's obesity pill. CVS had dropped Lilly's Zepound last summer but kept competitor Wegovy. It'll be back at Caremark October first. All three of the nation's largest pharmacy ⁠benefit managers ​now cover Lilly's full obesity medicine portfolio. https://www.reuters.com/legal/litigation/cvs-brings-back-coverage-lillys-obesity-drug-zepbound-2026-05-28/   More to come, including a new benefit from metformin for women, something new from Tidepool, big news for T1D in Austalia and more.. XX A new study suggests that higher long-term exposure to food colouring additives — including both synthetic and natural colourings commonly found in processed foods and beverages — may be associated with an increased risk of developing type 2 diabetes. Researchers analyzed data from more than 108,000 adults in the French NutriNet-Santé cohort between 2009 and 2023, following participants for a median of just over eight years. During that time, 1,131 participants developed type 2 diabetes. The study found that people with the highest intake of total food colouring additives had a 38% higher risk of developing type 2 diabetes compared with non- or low-consumers.   Several specific additives were linked to increased risk, including caramel colouring additives such as total caramel (E150 family), plain caramel (E150a), sulphite ammonia caramel (E150d), and beta-carotene (E160a). Additional associations were observed for curcumin (E100), anthocyanins (E163), paprika extract (E160c), lutein (E161b), and cochineal-derived colourings (E120). "Our findings revealed positive associations between widely consumed food colouring additives and type 2 diabetes incidence," the authors wrote, adding that further research is needed to better understand the mechanisms behind the findings and whether food colouring regulations should be reevaluated. https://www.medscape.com/viewarticle/use-common-food-colours-tied-high-type-2-diabetes-risk-2026a1000hes XX Big news for Australia – their Therapeutic Goods Administration (TGA) approves Tzield. Tzield is now approved in Australia to delay the onset of stage 3 (or clinical) T1D in people aged eight years and older with stage 2 T1D – the early, pre-symptomatic stage of the condition, where changes in blood glucose levels have begun but insulin therapy is not yet required. Breakthrough T1D Australia Chief Executive Officer, Sydney Yovic, said the approval represented a transformational moment for Australians affected by T1D. https://newshub.medianet.com.au/2026/05/landmark-approval-of-tzield-in-australia-ushers-in-a-new-era-of-delay-for-type-1-diabetes/155036/ XX https://www.theatlantic.com/health/2026/05/diabetes-pregnancy/687324/ XX A common diabetes drug may hold great potential to help with aging, even if scientists aren't exactly sure why. According to a study, the drug metformin doesn't just help patients to effectively manage their type 2 diabetes. it may also give older women a better chance of living to 90. Scientists in the US and Germany used data from a long-term US study of postmenopausal women.   Records for a total of 438 people were selected – half of whom took metformin to treat diabetes, and half of whom took a different diabetes drug, sulfonylurea.   While there are some caveats and asterisks to the study, those in the metformin group were calculated to have a 30 percent lower risk of dying before the age of 90 than those in the sulfonylurea group. The study used age 90 as the marker for 'exceptional' longevity. However, scientists aren't yet sure that the drug extends lifespan, especially in humans – which is part of the reason for this study. RCTs could follow further down the line to dig deeper into these results, the researchers suggest. In the meantime, as the global population continues to skew older, studies continue to find ways to keep us healthier for longer and reduce damage to the body as we age. https://www.sciencealert.com/a-common-diabetes-drug-is-linked-with-exceptional-longevity-in-women XX The American Diabetes Association® (ADA) will host the 2026 Scientific Sessions from June 5-8 in New Orleans. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening an expected audience of over 12,000 leading physicians, scientists, researchers, and healthcare professionals from around the globe. The premier diabetes meeting, which is also offered virtually, will feature the latest scientific findings in diabetes and obesity, where leading experts and peers will share findings in research for prevention, care, and cures at the Ernest N. Morial Convention Center. Key themes will include: Advancing obesity and metabolic health: Prevention, early detection, and disease modification: Improving cardiometabolic outcomes: Transforming care through innovation and access: New research will highlight how technology, artificial intelligence, and implementation strategies are reshaping diabetes care—reducing treatment burden, expanding access, and enabling more person-centered care. Advancing beta cell replacement and cure strategies: Fostering innovation: On Saturday, June 6, from 4:30-6:00 p.m., the Innovation Challenge, which debuted in 2023, invites emerging companies to pitch novel ideas to improve the lives of people living with diabetes. A panel of judges, with input from a live audience, determines which contestants will earn a private audience with potential funders. XX Tidepool, the nonprofit leader advancing innovation in diabetes technology, announced that Tidepool+ Direct Connect is now available through the Epic Showroom. Built on SMART on FHIR, Direct Connect brings interactive diabetes device data directly into Epic workflows, helping clinicians use patient data during routine care. "Tidepool has always focused on making diabetes data more accessible and actionable," said Brandon Arbiter, CEO. "We're excited to empower clinicians using Epic with insightful, intuitive patient data that fits directly into their encounter workflow so they can use it to improve care in the moment it matters."   Tidepool+ Direct Connect supports scalable deployment across Epic-enabled health systems. This architecture enables faster, more intuitive rollouts, enhancing Tidepool's existing EHR integration capabilities.   Direct Connect is part of Tidepool's ongoing work to improve how clinicians can use timely and relevant diabetes device data during patient visits to help drive better health outcomes.   The feature is now available in the Connection Hub of the Epic Showroom.   https://www.businesswire.com/news/home/20260527780274/en/Tidepool-Launches-in-Epic-Showroom-to-Bring-Diabetes-Device-Data-into-the-Point-of-Care XX

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel Skowronski, who suggested that obesity could become a solved disease within just a few generations of innovation.What does that mean for the millions of patients still fighting for access to GLP-1 medications like Zepbound, Mounjaro, and tirzepatide? And what is Lilly seeing in its pipeline that the rest of us can't?We dig into:Lilly's decision to stop disclosing its Phase 1 pipelineThe Camurus fluid crystal technology deal and what it means for long-acting GLP-1sEloralintide — Lilly's selective amylin agonist and potential dark horse in obesity medicineHow eloralintide compares to Novo Nordisk's cagrilintideWhy the future of obesity treatment is a toolbox, not a scoreboardThe access crisis: prior authorizations, insurance exclusions, Medicare, and Medicaid coverage gapsRetatrutide, quintuple agonists, and what's coming out of ADA 2026If you're on Zepbound, Wegovy, Ozempic, or any GLP-1 medication — or you're waiting for the next generation of obesity drugs — this episode is for you.

GLP-1 weight loss is about so much more than just the number on the scale.If you're taking Ozempic, Wegovy, Mounjaro, or Zepbound and feeling emotionally overwhelmed, anxious, conflicted, or even surprised by how much this journey is affecting your mindset—you are not alone.In this episode, Registered Dietitian and GLP-1 expert Gianna dives into the mental and emotional side of GLP-1 weight loss that almost nobody talks about.We're covering:How GLP-1 medications can change your relationship with foodWhat “food noise” is and why reduced food thoughts can feel emotionalWhy body image struggles don't automatically disappear with weight lossThe pressure of social media transformation cultureFear of weight regain and “what if this stops working?” thoughtsWhy needing a GLP-1 does not mean you failedIdentity shifts that can happen during major body changesHow to build a healthier mindset around sustainable weight lossWhether you're newly starting Ozempic, Wegovy, Mounjaro, or Zepbound—or deep into your GLP-1 journey—this episode is a reminder that your mental health matters too.Because sustainable health is not just about shrinking your body. It's about supporting your whole self.

In this episode, we break down the science behind GLP-1 medications including Ozempic, Wegovy, Zepbound, Mounjaro, semaglutide, and tirzepatide. Learn how GLP-1 weight loss medications work, their role in appetite suppression, insulin regulation, metabolic health, obesity treatment, and type 2 diabetes management.This evidence-based discussion explores GLP-1 benefits, side effects, muscle loss concerns, weight regain after stopping medication, nutrition considerations, digestion, metabolic adaptation, and sustainable wellness strategies. If you're considering GLP-1 medications or simply want a smarter conversation about obesity medicine, weight loss, longevity, and metabolic health, this episode delivers a clinically grounded wellness perspective. Disclaimer: This podcast is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The views shared are intended to support informed wellness conversations and should not replace individualized guidance from your physician or qualified healthcare provider. Always consult your healthcare team before making decisions regarding medications, treatment, nutrition, or health management.

Mazel morons! This week, we're back at you with the original recipe and we're coming in hot. From millennial parents sipping Mai Tais in the dugout , to a Knicks away game and a suite full of Hasidic Jews, we're recapping our Mother's days and thoughts on etiquette across the board. Plus, we're getting real about the Zepbound blues and consulting a cheese witch to read our future in a block of cheddar. What are ya nuts? Love ya! Write us! goodguyspodcast1@gmail.com Follow us on Instagram and TikTok!  Please note that this episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode. Produced by Dear Media. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dealing with constipation, nausea, or bloating on a GLP-1 like Ozempic, Wegovy, Mounjaro, or Zepbound?You are definitely not alone.Digestive side effects are some of the most common challenges people experience on GLP-1 medications—but there's a huge difference between expected side effects and feeling miserable all the time.In this episode, Registered Dietitian and GLP-1 expert Gianna breaks down the science behind GLP-1 digestive side effects, including why they happen, what evidence-based strategies can actually help, and the biggest mistakes that may be making symptoms worse.We're covering:Why GLP-1 medications can cause constipation, nausea, and bloatingHow delayed gastric emptying impacts digestionWhy under-eating can actually worsen side effectsWhat to eat when nausea makes food unappealingEvidence-based strategies for constipation reliefHow hydration and meal structure affect symptomsThe truth about fiber on GLP-1sWhen side effects are no longer considered “normal”The social media advice you should probably ignoreWhether you're taking Ozempic, Wegovy, Mounjaro, or Zepbound, this episode will help you better understand what's happening in your body—and how to support your digestion without extreme restriction or fear.

What happens when Amazon turns weight loss into a one-click purchase?This week on Slay, Louise Hazel breaks down the shocking news that Amazon is stepping into the GLP-1 market—making medications like Ozempic, Wegovy and Zepbound more accessible than ever before.But beneath the headlines lies a bigger question:Are women becoming healthier… or simply thinner?In this episode: ✓ What Amazon's GLP-1 launch means✓ Why millions more women may start taking weight-loss drugs ✓ The hidden muscle loss crisis nobody is talking about ✓ How pharmaceutical pressure may reshape body image ✓ Why strength training matters now more than everThis is not anti-GLP-1.This is pro-informed women.Because no injection replaces muscle.No shortcut replaces strength.The future belongs to strong women.Comment APP and I'll DM you the waitlist link for the new Slay app—your new strength companion.#SlayPodcast #GLP1 #Ozempic #WomenHealth #StrengthTraining #FitnessNews #LouiseHazel #WomenWhoLift #HealthyWeightLoss #Amazon

Three new GLP-1 studies, why every food is suddenly "high protein," the Bethenny Frankel shoe drama blowing up Instagram, and why I'm on a ketamine table as you listen. Three new studies just shifted the GLP-1 conversation, and not in the direction women have been hearing about. Chalene digs into what's actually happening to muscle and bone density, why the rebound after coming off matters more than anyone's talking about, and the three questions every woman on Ozempic, Wegovy, Mounjaro, or Zepbound should bring to her next doctor's appointment. She also gets into why every grocery aisle suddenly screams "high protein," and why this whole moment is starting to feel suspiciously like the Snackwell cookie era. There's a simple protein target that works without tracking macros, and Chalene walks through how she's using it. Then she breaks down the Bethenny Frankel shoe drama that took over Instagram this week. What the shoe brand founder got wrong, what Bethenny got wrong, and the rules of brand partnerships that almost nobody outside the influencer world understands. Finally, a personal update. As you're listening to this, Chalene is on the table for another medically supervised ketamine treatment with Dr. Andrew Levinson. She shares why she went back for a third session, what the last journey taught her about control, and who this kind of work is really for.  

The vast majority of employer health plans do not cover GLP-1s for weight loss. But roughly 20% do, many believing it will help their bottom line. Perhaps when employees take Wegovy or Zepbound, they'll need less medical care tied to health issues from obesity. Today on the show, can GLP-1s save employers money in the long run?Fact checking by Sierra Juarez.Your Next Listen — No healthcare premiums? In this economy?! Here's how.— Julie Wernau's original episode with TradeoffsConnect with The Indicator — Sign up for The Indicator's brand new newsletter— Find our socials, YouTube and more!— For sponsor-free episodes, subscribe to NPR+ See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.NPR Privacy Policy

Colorectal cancer is now the leading cancer killer in adults under 50, and patients in their 20s are presenting with metastatic disease that has nothing to do with family history. Most physicians are still telling young patients with rectal bleeding that it's probably just hemorrhoids and that's costing lives.In this episode, Dr. Gabrielle Lyon sits down with Dr. Michelle Pearlman, a board-certified gastroenterologist and founder of a Miami-based gastro-metabolic clinic, to discuss:The specific warning signs every adult under 50 should never ignore, regardless of age including rectal bleeding, unintentional weight loss, and persistent abdominal painWhy GLP-1 medications like Ozempic and Zepbound are being miscategorized as weight loss drugs when they're actually metabolic reprogrammers with applications in fatty liver, sleep apnea, and inflammationThe protein, fiber, and resistance training protocol Dr. Pearlman uses to protect muscle mass in patients on GLP-1 therapyHow hormone replacement therapy combined with GLP-1s is changing body composition outcomes for perimenopausal women and why current guidelines are still 20 years behind the dataDr. Pearlman's personal osteoporosis diagnosis at 39, despite being a lifelong bodybuilder, and what it revealed about the diagnostic gaps in standard medicineThis conversation gives you the framework to recognize the warning signs most physicians are still missing, and the foundational habits; nutrition, resistance training, and hormone optimization that protect your gut, bones, and muscle through midlife and beyond.Thank you to our sponsors: Cozy Earth - Go to https://bit.ly/4teXQhz for up to 20% off! Timeline - Get 20% off your Mitopure order at https://bit.ly/4eLBWhB Lucy - Get 20% off your next order with code DRLYON at https://bit.ly/42HiUlc, or find yours in store at https://bit.ly/3RfGnYa Amp - Visit https://bit.ly/3RcmqBz to get your AI-powered at-home gym for smarter, personalized training.Explore More from Dr. Gabrielle LyonPremium Podcast Subscription: Ad-free episodes, key takeaway summaries, exclusive Q&A, and behind-the-scenes content https://foreverstrong.supercast.comWeekly newsletter: Recipes, podcast updates, and practical weekly insights https://drgabriellelyon.com/sign-up/Apply to become a patient: Personalized care with Dr. Lyon's clinical team https://drgabriellelyon.com/new-patient-inquiry/Find Dr. Michelle Pearlman at:Instagram: https://www.instagram.com/michellepearlmanmd/ Website: https://pearlmanmds.com/michelle-pearlman-md/ Connect with Dr. Gabrielle LyonInstagram: https://www.instagram.com/drgabriellelyon/TikTok: https://www.tiktok.com/@drgabriellelyonX (Twitter): https://x.com/drgabriellelyonFacebook: https://www.facebook.com/doctorgabriellelyonChapters00:00 - Introduction: Colorectal cancer under 5001:15 - The gastro-metabolic approach explained03:30 - Why nutrition isn't taught in GI fellowship05:45 - When the colonoscopy is normal but patients suffer07:00 - Weight, reflux, and visceral fat09:15 - PPIs, bone density, and long-term risk11:30 - Three things to never do for gut health14:00 - Ultra-processed food and early-onset cancer16:45 - Rectal bleeding, warning signs, and age19:00 - Screening guidelines and the obesity gap22:30 - GLP-1 medications: history and mechanism27:15 - Hunger, cravings, and food noise30:00 - The stigma around metabolic medications33:45 - Side effects: nausea, reflux, constipation38:30 - Compounded formulations and pharmacy safety42:00 - Hair loss, protein, and supplementation45:15 - Pill versus injection delivery systems49:30 - Fiber, the microbiome, and short-chain fatty acids54:00 - GLP-1s plus hormone replacement therapy58:45 - Testosterone, Kyzatrex, and women's bone health1:03:00 - Pearlman's osteoporosis diagnosis at 391:09:30 - The diagnostic gap in standard medicine1:14:00 - Building Bite MD and the future of nutrition tech Disclaimers: This episode includes paid sponsorships. The Dr. Gabrielle Lyon Podcast and YouTube are for general information purposes only and do not constitute the practice of medicine, nursing, or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast, YouTube, or materials linked from this podcast or YouTube is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professional for any such conditions.

It's In The News, where we bring you the top diabetes stories and headlines happening now. Top stories this week: Dexcom shares details of its next generation CGM, T1D and GLP-1 studies, weight loss management on GLP-1 medications updates, all-in-one CGM and pump, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: XX Dexcom announces some features of it's next generation CGM – the G8. We've been talking about this with CEO Jake Leach for a while now – it will be a 50% smaller with what they're calling advanced sensing capabilities. According to Leach, G8 will adapt to the physiologic variability of each user. It has additional technology built in, based on a new silicon chip design and algorithm. 15 day wear is now the baseline for all Dexcom sensors moving forward. At launch the G8 will only measure glucose but the plan is for a multi-analyte version to follow. That would measure ketones and potassium. Ketones we know – but potassium is very important for people with kidney and possible for people taking some diabetes meds. It's an interesting space to watch.. btw, analyte is just a medical word for the specific thing you're measuring – the target of the test you're running. we're going to hear that word a lot I think..   Looks like an FDA submission for the G8 next year.. with an outside the US launch the following year. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ XX Glucotrack has submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE, that's investigational device exemption and would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack's device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. The implant goes five centimeters within the subclavian vein. Glucotrack's active implantable device has a small battery and some electronics that go just under the skin in the pectoral region. The location of the implant is not in a major vessel, but the implant can measure real-time glucose levels as pulsatile blood flows over the tip of the sensor. https://www.drugdeliverybusiness.com/glucotrack-submits-long-term-implantable-cbgm-fda-ide/ XX PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. However, this system would be one device that features both the pump and CGM technology.   PharmaSens and SiBionics also have a collaboration aimed at developing the all-in-one solution. They are jointly developing the next-generation Niia insulin patch pump with a SiBionics CGM. PharmaSens expects a second feasibility study in the second quarter to evaluate the next-generation pump with SiBionics' CGM.   PharmaSens says the clinical feasibility study of Niia demonstrated for the first time ever that the combined offering is, in fact, feasible. It believes its device addresses the need for alternatives to multi-device diabetes management. systems.   Aggregated MARD for the investigational device came in at 11.6%. A MARD target of less than 10% is considered ideal for CGM devices, but PharmaSens said that, in the context of the early feasibility study, the results were encouraging and provide evidence supporting the development of an all-in-one system. https://www.drugdeliverybusiness.com/pharmasens-efs-insulin-patch-pump-cgm/ XX   XX ViCentra launches the newest version of the Kaleido pump system in Europe. This is that small colorful pump, with Diabeloops algorithm and the Dexcom G7. It'll be in Germany and the Netherlands later this summer. https://hellokaleido.com/vicentra-announces-commercial-launch-of-new-smartphone-controlled-kaleido-automated-insulin-delivery-patch-pump-system/--   XX Diabeloop just got CE Mark approval for DBLG2 integrations – it's latest AID platform the company has kicked off the gradual European launch of the technology. It currently offers DBLG2 as a smartphone application on Android, with iOS integration coming soon. As you just heard, it's integrated with kaleido and the company says it plans to make additional configuration for DBLG2 with alternative pumps "available soon." Running on a user's smartphone, DBLG2 works as a self-learning algorithm. It continuously analyzes glucose data, calculates insulin needs in real time and automatically adjusts delivery. https://www.drugdeliverybusiness.com/diabeloop-fda-next-gen-algorithm-g7/   XX Among adults with type 1 diabetes (T1D), the initiation of GLP-1-based therapy was associated with a lower risk for all-cause death, several cardiovascular outcomes, all-cause hospitalisations, and hypoglycaemia, without a higher risk for diabetic ketoacidosis.   METHODOLOGY: Researchers in Greece conducted a retrospective cohort study utilising real-world data from a global health research network to evaluate the association between GLP-1-based therapy and cardiovascular and renal outcomes in adults with T1D. A total of 4088 patients receiving GLP-1-based therapies (median age, 43 years; 34.3% men) were propensity score matched with an equal number of patients not receiving the treatment. The risk for hypoglycaemia was lower with GLP-1-based therapy (hazard ratio, 0.72; P = .021); however, the risk for diabetic ketoacidosis did not differ significantly between the two groups. https://www.medscape.com/viewarticle/glp-1-drugs-tied-cardiovascular-benefits-t1d-2026a1000fbx   XX Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively.   "Weight regain remains one of the biggest challenges in obesity care, and is often the result of treatment interruptions that cause biology to work against patients, undoing the progress they've made," said Louis J. Aronne, M.D., FACP, DABOM, founder and Chair Emeritus of the American Board of Obesity Medicine, former president of The Obesity Society, Fellow of the American College of Physicians, world-renowned obesity specialist and Lilly consultant. "These medicines can be used for long-term maintenance today, and results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN provide additional evidence of their potential when switching from higher doses of injectable incretin therapy." https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-and-lower-dose-zepbound-helped-people-maintain XX Scientists in Sweden have developed a more reliable way to create insulin-producing cells from human stem cells. These lab-grown cells not only respond strongly to glucose but were also able to restore blood sugar control when transplanted into diabetic mice. When transplanted into diabetic mice, the cells gradually restored the animals' ability to regulate blood sugar. Long way to go, as we say with most of these mice studies. https://www.sciencedaily.com/releases/2026/05/260505234620.htm XX Interesting look at how the body controls sugar storage – apparently this finding challenges long-standing biology concepts and could open new directions for disease treatment. Published in Nature, the study describes a potential method for directly reducing glycogen, the stored form of sugar in the body. These scientists discovered that glycogen can be directly regulated by ubiquitin, a protein best known for marking damaged proteins for recycling or removal. The study is the first to show that ubiquitin can regulate glycogen in humans, overturning more than 50 years of scientific understanding. Excess glycogen is also associated with more common health problems, including diabetes, obesity, liver disease, and heart disease.       https://scitechdaily.com/scientists-just-rewrote-biology-hidden-mechanism-could-transform-diabetes-treatment/ XX A new Oklahoma law will give parents the option to have their children screened for Type 1 Diabetes.   The measure passed with overwhelming bipartisan support in the Legislature and takes effect Nov 1. Oklahoma consistently ranks among the states with the highest rates of diabetes and diabetes-related deaths. The law gives parents access to antibody testing that can detect risk years before symptoms develop, helping families take preventive action and avoid emergency room visits. https://journalrecord.com/2026/05/11/oklahoma-law-expands-access-type-1-diabetes-screening/ XX More to come including a new study trying to figure out why some people are more likely to develop diabetes, a look at cannabis and preventing metabolic disorders, and XX   A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. The study involved a deep dive into islet cell function that is linked to donor traits associated with observable characteristics, or phenotype, such as sex, race and ethnicity, as well as genetic information, or genotype, including predicted ancestry and genetic risk for both type 1 and type 2 diabetes. The findings highlight that islet cell composition, rather than the physical size and shape of islets, is a key factor in regulating hormone release. The team found that the makeup of pancreatic islets plays a major role in how effectively they release insulin and glucagon — key hormones that regulate blood glucose. Islets with a higher proportion of insulin-producing beta cells showed stronger insulin secretion in response to various stimuli, while higher levels of alpha and delta cells were generally linked to reduced insulin output. In addition, the researchers found that islet hormone secretion is affected by donor traits, such as sex, race and ethnicity and their genetic makeup, including ancestry predicted from genetic testing and genetic risk for type 2 diabetes. Combined, the findings of the study have significant implications for understanding the factors that may predispose people to diabetes. "This study is the tip of the iceberg," said Dr. Evans-Molina. "We hope this dataset becomes useful to the entire diabetes research community and that researchers use it to answer questions about the genotype-phenotype correlation within these data."   https://www.nih.gov/news-events/news-releases/nih-funded-study-maps-human-pancreatic-islet-cells-offering-new-clues-diabetes-risk XX XX XX Research published recently in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients.   "This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer – whether this is related to weight control, improve cardiovascular health or other mechanisms remains to be studied," said study senior author Bernard F. Fuemmeler, Ph.D., MPH, associate director for population sciences and the Gordon D. Ginder, M.D., Chair in Cancer Research at VCU Massey Comprehensive Cancer Center.   Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival.   What are GLP-1 drugs? Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approved to treat type 2 diabetes in 2005 and weight management in 2021. Impacts on breast cancer survival and recurrence are still unclear. Since 2020, the use of these drugs has increased dramatically, where approximately 12% of Americans have used GLP-1s for weight loss, according to a RAND report.   The research findings Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes.   GLP-1 RA use was associated with an overall lower risk of death from any cause over a 10-year follow-up period among breast cancer patients. Additionally, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment.   "Our findings align with emerging preclinical research and contribute to a growing body of literature related to GLP-1 RA use in oncology settings," said study lead author Kristina L. Tatum, PsyD, MS, of the VCU School of Public Health.   What's next? Further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes. The research team intends to further evaluate these correlations through randomized clinical trials.   "Our study underscores the potential of GLP-1 RAs as an adjunct strategy for improving cancer-related outcomes among patients with breast cancer, although clinical trials are needed to inform effective therapeutic approaches and clinical decision making," Fuemmeler said. https://www.oncology-central.com/could-glp-1-receptor-agonists-improve-outcomes-for-breast-cancer-patients-with-obesity-or-with-type-2-diabetes/ XX Researchers at UC Riverside gave cannabis to obese mice and found that not only did the rodents lose weight, but when given a concentrated cannabis oil, the mice also saw striking benefits in their metabolic function. DiPatrizio said his team studied the issue to better understand why cannabis users show significant reductions in weight and risk for diabetes compared with nonusers. "We would think that chronic cannabis users would be eating more and weigh more, but it's just the opposite," DiPatrizio said. Scientists are increasingly examining the possibility that cannabis compounds could fight obesity or metabolic disorders like diabetes. Cannabinoids interact with the body's endocannabinoid system, which partially controls nearly every aspect of our physiology, including metabolism and appetite. That creates the possibility that targeting this widespread system could unlock new therapies for these conditions. https://www.sfgate.com/cannabis/article/cannabis-weight-loss-california-study-22255328.php XX A new campaign launched by diaTribe and Genentech aims to empower and educate people about diabetes-related eye disease. Here's what you can do today to protect your eye health. To help address these barriers, diaTribe and Genentech partnered to launch All Eyes on DME, a new campaign that aims to spread awareness and educate people at-risk for or living with diabetes-related eye conditions like DME. Also partnering in the campaign is actor and comedian Damon Wayans, who wanted to share his journey (and, of course, a joke or two) with type 2 diabetes to open up the conversation about what is often a stigmatized or less talked about topic: eye health and diabetes.   One of these important conversations happened recently at the All Eyes on DME launch in New York City, where Wayans joined a panel of experts, advocates, and people living with DME to talk about diabetes-related eye disease and how to help prevent it. https://www.alleyesondme.com/dme-in-the-spotlight.html https://diatribe.org/diabetes-complications/all-eyes-dme-new-campaign-spotlights-eye-health-and-diabetes

Noticing more hair shedding since starting a GLP-1 like Ozempic, Wegovy, Mounjaro, or Zepbound?You are not alone—and despite what social media might say, there's a lot of misinformation about hair loss on GLP-1 medications.In this episode, Registered Dietitian and GLP-1 expert Gianna breaks down the science behind hair loss and rapid weight loss, including what current evidence actually suggests about why shedding may happen during a GLP-1 journey.We're covering:Whether GLP-1 medications directly cause hair lossHow rapid weight loss can impact the hair growth cycleWhat telogen effluvium is and why it mattersThe connection between low protein intake and hair sheddingWhy under-eating can make symptoms worseNutritional factors that may play a role in hair healthWhen to talk to your healthcare provider about symptomsThe biggest mistakes people make when hair shedding startsIf you've been feeling anxious, overwhelmed, or frustrated by changes in your hair while taking Ozempic, Wegovy, Mounjaro, or Zepbound, this episode will help you better understand what may be happening in your body—and what to focus on moving forward.

People keep asking the same question: what's actually the difference between all these weight loss medications?  Ozempic. Wegovy. Mounjaro. Zepbound. Foundayo. Wegovy pill. Some of these medications are injections, some are pills, some are FDA-approved for diabetes, others for weight loss, and some are actually the same medication with completely different brand names. So I'm breaking it all down for you today — in plain language — because the confusion alone is keeping people from getting the treatment they need. The real problem isn't just the brand names. It's that without knowing exactly how these medications differ, patients end up on the wrong one, pay out of pocket unnecessarily, or give up when insurance denies them. You deserve better than that. Once you understand what each one actually does, the whole picture becomes much clearer. Listen now!   Episode Highlights: Why Ozempic and Wegovy are the same medication and why the difference still matters How tirzepatide (Mounjaro/Zepbound) works on two hormone pathways and why it tends to produce greater weight loss The new oral options — Foundayo and Wegovy pill — and who they're actually right for Real average weight loss numbers from clinical trials, by medication How insurance covers (or denies) each one and what I tell my patients when it does Who may be a candidate for these medications   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

This week, This Week in Pharmacy examines several stories shaping the business, clinical, and legal future of pharmacy practice. In TWIRx News from Pharmacy Times from Megan Maroney, PharmD, BCPP, FAAPP, focused on antidepressant use, withdrawal concerns, deprescribing, and shared decision-making. The key takeaway: patients should never stop antidepressants abruptly. Pharmacists can play a vital role in reducing stigma, educating patients, and supporting safe conversations about tapering, side effects, and long-term treatment. In health technology news, FDB research presented at the 2026 AMIA Amplify Informatics Conference found that patient-specific, risk-based medication guidance reduced pharmacy alert volume by 70% in a high-volume community pharmacy setting. The model consolidates alerts into one actionable message tied to the patient's most relevant risk, helping reduce alert fatigue and improve workflow. Finally, we review a federal court ruling in Eli Lilly's lawsuit against Houston-based Empower Pharmacy over compounded tirzepatide versions of Mounjaro and Zepbound. The judge dismissed key federal trademark and Texas unfair competition claims, while allowing other state claims to continue. Andy Crawford, with Keysource is back on TWIRx talking about the U.S. Supreme Court taking up Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., a case that could significantly affect generic drug competition. At issue is whether Hikma's marketing materials and public communications around its generic version of Amarin's fish oil-based cardiovascular drug improperly promoted a still-patented use. Hikma and the broader generic industry argue the case is about protecting “skinny label” rules, which allow generics to carve out patented indications while still bringing lower-cost medications to market. For pharmacists, the decision could influence generic availability, substitution confidence, pricing pressure, and how manufacturers communicate with providers and pharmacies. Thanks to our sponsors, CassianRx and IPC, for supporting independent pharmacy, innovation, and the future of patient-centered care.

You already know GLP-1 medications like Ozempic, Wegovy, and Zepbound can be game changers for weight loss. But could they also be quietly protecting your brain from addiction?In this episode, Lisa Oldson, MD breaks down a landmark new study published in Frontiers in Psychiatry, the largest real-world analysis of its kind, which found that people taking GLP-1 medications were dramatically less likely to develop alcohol, opioid, nicotine, and cocaine use disorders. The numbers are stunning, and the brain science behind them is even more fascinating.Whether you're on a GLP-1 medication, considering one, or simply trying to understand your own cravings and habits, this episode offers a compassionate, science-backed perspective that might just shift the way you think about willpower, the brain, weight, wine, and behavior change.Thanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also, we'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.The Smart Weight Loss Coaching Podcast is for informational purposes only and does not constitute medical advice. Always consult your physician or a qualified healthcare provider before starting, stopping, or changing any medication.

This week Shawn gambles and wins big, while Damian gambles and loses.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the dynamic shifts and breakthroughs shaping this ever-evolving industry. In a significant regulatory update, the resignation of FDA Commissioner Marty Makary has stirred discussions across the pharmaceutical landscape. Over his 13-month tenure, Makary faced considerable scrutiny for his controversial decisions, including the rejection of several rare disease drugs. This leadership change at the FDA may herald a period of uncertainty as the agency searches for new direction amidst criticisms and operational challenges. The implications are vast, potentially affecting drug approval processes and public health policies, making it crucial for stakeholders to watch closely how the agency adapts to this transition. Simultaneously, Takeda's announcement to lay off 4,500 employees marks a strategic move to streamline operations and focus on core competencies. This decision reflects a broader industry trend where companies are optimizing their structures to enhance financial health in a highly competitive market. The cost savings from this restructuring are expected to be substantial, allowing Takeda to pivot towards more sustainable business models and focus on areas that promise future growth. Eli Lilly and Novo Nordisk continue to lead in drug development with their GLP-1 receptor agonists. Both companies have reported promising data on early response and long-term weight loss maintenance in patients, positioning their therapies as pivotal in treating obesity. Eli Lilly's obesity treatments Foundayo (orforglipron) and Zepbound (tirzepatide) have shown sustained weight-loss maintenance in Phase 3 trials, reinforcing their efficacy in metabolic health interventions. These developments not only highlight the intense competition in the GLP-1 space but also underscore the potential impact on addressing global obesity challenges effectively. The strategic landscape of mergers and acquisitions is also evolving with Merck KGaA's announcement to bolster its pipeline through strategic M&A activities. This move is emblematic of an industry-wide strategy where companies seek external innovation to fill pipeline gaps, ensuring sustained growth and competitiveness. In a related vein, BioMarin's $4.8 billion acquisition of Amicus Therapeutics signifies a firm commitment to addressing unmet needs in rare diseases, illustrating how consolidation can enhance capabilities in niche markets with significant potential. In vaccine development, Valneva's decision to reduce its workforce by up to 15% highlights ongoing challenges in the sector, particularly for travel-related vaccines affected by global market trends. This restructuring is indicative of the volatility faced by companies as they adapt strategies for long-term sustainability amidst shifting consumer behaviors. Pfizer's expansion into Europe with its hemophilia treatment Hympavzi marks a critical regulatory milestone, broadening its market presence and offering expanded therapeutic options for patients. This approval not only strengthens Pfizer's foothold in the hemophilia market but also exemplifies the global reach of innovative treatments. Technological integration continues to revolutionize R&D processes, as evidenced by AstraZeneca's licensing agreement with Owkin for AI capabilities. This partnership aims to harness AI-driven insights for drug discovery, showcasing how technology is reshaping traditional research methodologies and enhancing efficiency. Similarly, advancements in AI-powered diagnostics are evidenced by Boehringer Ingelheim's collaboration with Brainomix in pulmonary fibrosis imaging, reflecting broader trends towards personalized medicine through precise disease characterization. Kyverna Therapeutics is advancing in cell therapy with Support the show

Diet culture doesn't always show up as a “diet.” Sometimes it sounds like “I can't have that,” “I'll start Monday,” or “I ruined it so I might as well keep going.” We get real about how those scripts kept us stuck for decades, and what finally helped us build healthy habits we can actually live with after losing over 100 pounds each.We walk through the difference between dramatic resets and sustainable weight loss: smaller portions, meal prep that makes eating easier, and the kind of flexibility that keeps you consistent even when sleep is bad or plans change. We also talk honestly about tools like bariatric surgery and GLP-1 medications (including Zepbound) and why they're helpful for some people, but never a substitute for mindset, nutrition basics, and routines that support long-term weight maintenance.Then we zoom out to the bigger stuff: the restriction binge cycle, the pressure of the scale, and why health is more than a number. We share how we think about non-scale victories like energy, strength, blood work, and how your clothes fit, plus how we try to raise kids with food awareness instead of food shame. We also call out social media “highlight reel” bodies and why finding authentic support matters.If any of this hits home, take one next best step and build from there. Subscribe, share this with a friend who's tired of starting over, and leave a review so more people can find a healthier way forward.Follow Justy & Steph on Instagram, where they share their weight loss journey and road to living a happy & healthy lifestyle.@we.are.losing.it If you prefer video to see us talk through our topics, you can watch us on YouTube. https://youtube.com/@wearelosingitShow your support by hitting download, like & subscribe! We truly appreciate each and every one of you!!

Do you actually need to exercise on a GLP-1?If you're taking Ozempic, Wegovy, Mounjaro, or Zepbound and wondering whether workouts really matter for weight loss, this episode is for you.In this episode, Registered Dietitian and Certified Personal Trainer Gianna breaks down the science behind fat loss vs muscle loss on GLP-1 medications, and why movement, strength training, and protein intake matter for long-term success.Spoiler alert: losing weight is not automatically the same thing as improving body composition, protecting muscle, or supporting your metabolism.We're covering:Whether exercise is necessary on a GLP-1Why muscle loss can happen during rapid weight lossThe difference between fat loss and lean mass lossWhy strength training matters for metabolism and long-term resultsThe best types of exercise to focus on while taking a GLP-1How much exercise you actually needWhy protein and resistance training work togetherThe biggest exercise myths people believe about GLP-1 medicationsWhether you're brand new to GLP-1s or already losing weight on Ozempic, Wegovy, Mounjaro, or Zepbound, this episode will help you focus on building a healthier, stronger body (not just a smaller one).⭐ LOVE THIS EPISODE?If this episode helped you, it would mean so much if you:Follow the podcastLeave a rating + reviewShare this with a GLP-1 bestie who needs it

Here's a shocking number: One out of eight American adults is taking a GLP-1, like Ozempic or Zepbound, according to a KFF poll. GLP-1s are the biggest pharmaceutical story since antidepressants. But there's still so much we don't know. “We're only at the beginning of what's been called this Ozempic era,” the journalist Julia Belluz told me. “I think we're really just at the beginning of discovering the benefits and the harms of these drugs.” These discoveries begin in the research but are also expanding into how we think about our punishing beauty standards and the blurry lines between illness and wellness. Belluz is a contributing Opinion writer and the author, with Kevin Hall, of “Food Intelligence.” She's one of the best health and science reporters I know and has been reporting on GLP-1s for years. In this conversation, Belluz takes me through what we know — and don't know — about GLP-1s, their unexpected uses, how they are clashing with a culture obsessed with thinness and looksmaxxing, and whether everyone should be on them. Mentioned: “The obesity pay gap is worse than previously thought” by The Economist “The Great Ozempic Experiment” by Julia Belluz Book Recommendations: Behave by Robert M. Sapolsky The Poison Squad by Deborah Blum Ultra-Processed People by Chris van Tulleken Thoughts? Guest suggestions? Email us at ezrakleinshow@nytimes.com. You can find transcripts (posted midday) and more episodes of “The Ezra Klein Show” at nytimes.com/ezra-klein-podcast, and you can find Ezra on Twitter @ezraklein. Book recommendations from all our guests are listed at https://www.nytimes.com/article/ezra-klein-show-book-recs. This episode of “The Ezra Klein Show” was produced by Annie Galvin. Fact-checking by Michelle Harris, with Julie Beer. Our senior engineer is Jeff Geld, with additional mixing by Johnny Simon. Our recording engineer is Aman Sahota. Our executive producer is Claire Gordon. The show's production team also includes Marie Cascione, Rollin Hu, Kristin Lin, Emma Kehlbeck, Jack McCordick, Marina King and Jan Kobal. Original music by Pat McCusker. Audience strategy by Shannon Busta. The director of New York Times Opinion Audio is Annie-Rose Strasser. Transcript editing by Sarah Murphy and Marlaine Glicksman. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

GLP-1 medications like Ozempic and Wegovy are everywhere right now. But what do they actually do? And who are they for?Today we're joined by Dr. Spencer Nadolsky, also known as “The Doc Who Lifts.” He's an obesity and lipid specialist physician, founder of Vineyard and ChefRX, and co-host of the Docs Who Lift podcast.Dr. Nadolsky breaks down the science, myths, and real-life impact of GLP-1s, including:What it feels like to be on GLP-1sExpected weight loss resultsComparison of weight loss drugs: Ozempic vs Wegovy vs ZepboundSide effects What happens when you stop taking themAre they ruining metabolism? Muscle? Bones? Relationships!? Are GLP-1s the solution to obesity?Tune in and find out. Links:IG: https://www.instagram.com/drnadolsky/Vineyard: https://joinvineyard.com/ChefRX: https://orders.chefrx.co/get-startedThe Docs Who Lift Podcast: https://drspencer.com/podcast/(00:00:00) Welcome to the podcast. Meet Dr. Nadolsky.(00:06:03) Simple explanation GLP-1s(00:08:23) Who GLP-1s are for(00:11:26) Ozempic vs Wegovy vs Zepbound(00:12:48) Expected weight loss results(00:15:06) Side effects explained(00:23:42) What it feels like to be on GLP-1s(00:27:16) Why people are so emotional about GLP-1s(00:33:27) Are GLP-1s the solution to obesity?(00:39:18) The #1 thing everyone should do for their health(00:42:35) Where to find Dr. NadolskyWant to leave the TTSL Podcast a voicemail? We love your questions and adore hearing from you. https://www.speakpipe.com/TheThickThighsSaveLivesPodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The CVG Nation app, for ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠iPhone⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The CVG Nation app, for Android⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fitness FB Group⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Thick Thighs Save Lives Workout Programs⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Constantly Varied Gear's ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Workout Leggings⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The CVG Nation App, for iPhone: https://apps.apple.com/us/app/cvg-nation/id1544802693The CVG Nation App, for Android: https://play.google.com/store/apps/details?id=uk.co.disciplemedia.cvgnationOur Fitness Facebook Group: https://www.facebook.com/groups/416198445414413Thick Thighs Save Lives Workout Programs: https://www.constantlyvariedgear.com/pages/ttsl-daily-lander-with-ebooksConstantly Varied Gear's Workout Leggings: https://www.constantlyvariedgear.com/ 

What do you actually eat on a GLP-1?If you're taking a GLP-1 like Ozempic, Wegovy, Mounjaro, or Zepbound, figuring out what to eat can feel confusing—especially when your appetite is low, you get full quickly, or nothing sounds good.In this episode, Registered Dietitian and GLP-1 expert Gianna walks you through a realistic “what I eat in a day” on a GLP-1—focused on simple meals that support energy, protein intake, muscle retention, and sustainable weight loss.This isn't a restrictive meal plan or a “perfect day of eating.”It's a practical, flexible framework you can actually use in your real life.We're covering:What to eat on a GLP-1 when you're not very hungryHow to structure meals for better energy and resultsEasy, protein-forward breakfast, lunch, dinner, and snack ideasHow to keep meals simple without overthinking itWhy under-eating can backfire on GLP-1 medicationsWhether you're just starting Ozempic, Wegovy, Mounjaro, or Zepbound—or you've been on one for a while—this episode will help you feel more confident, less overwhelmed, and more consistent with your nutrition. ✨ The GLP-1 Circle Membership is open, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey with founding rates starting at $49/month!  Learn more and join here!

Home from space, the crew of the Artemis II stops by the Squawk set. Commander Reid Wiseman, Pilot Victor Glover, and Mission Specialists Christina Koch and Jeremy Hansen discuss their brave journey around the moon, the newest frontiers, the emotional and physical toll of takeoff and reentry, and handling snafus–like smoke alarms and toilet troubles–while in space. Eli Lilly CEO David Ricks discusses the drugmaker's big financial quarter in an exclusive interview. He shares the first prescription numbers of Lilly's newest GLP-1 pill, Foundayo, as well as how it differs from Zepbound and Novo Nordisk's Wegovy. Plus, Anthropic is in talks to raise funds at a $900B valuation, the Saudi Public Investment Fund will stop funding the LIV Golf League, and Jerome Powell will remain on the Fed's Board of Governors after his time as Chairman ends.    Steve Liesman - 3:17 Angelica Peebles & David Ricks - 17:12 Artemis II Crew - 32:06   In this episode: Artemis Crew, @NASAArtemis Steve Liesman, @steveliesman Angelica Peebles, @angelicapeebles Joe Kernen, @JoeSquawk Andrew Ross Sorkin, @andrewrsorkin Cameron Costa, @CameronCostaNY Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ozempic, Wegovy, Mounjaro, Zepbound. Todo el mundo los conoce. Nadie te está diciendo la verdad completa. ¿Quieres ser parte de la Ruta Ganadora? Agenda tu llamada GRATIS con Carlos para que veas de qué se trata y cómo puede cambiar el rumbo de tu vida.

Market update for Thursday April 30, 2026Check out the Public app for incredible investing tools and to support the show (LINK)Follow us on Instagram (@TheRundownDaily) for bonus content and instant reactions.In today's episode, Zaid covers:Jerome Powell's last Fed meeting and what comes nextGoogle crushes earnings, cloud revenue surges 63% to $20BAmazon's AWS grows 28%, fastest pace in nearly four yearsMicrosoft beats estimates but stock drops as cloud momentum stallsMeta revenue jumps 33% but stock tanks on raised AI spending and user declineEli Lilly blows past estimates, Zepbound and Mounjaro sales skyrocketFun fact; 69% of Polymarket traders are losing money

We hadden wel tientallen verschillende titels kunnen verzinnen, want het was een beursdag met heel veel onderwerpen. Vier Amerikaanse techreuzen die met kwartaalcijfers kwamen, maar ook een hele trits aan AEX-bedrijven. Het was me het dagje wel. We hebben het deze aflevering onder meer over Alphabet en Meta. Waarom kan Alphabet dit jaar 190 miljard dollar uitgeven en volgend jaar zelfs 'significant' meer en daarvoor beloond worden door aandeelhouders? Helemaal omdat het aandeel Meta op dat nieuws gedumpt wordt. Verder praten we je bij over de cijfers van ING, Magnum, Unilever, AirFrance-KLM en Eli Lilly. Ook hoor je over de tactiek van Universal Music Group. Dat vindt het overnamebod van Bill Ackmann veel te weinig en kiest daarom de aanval: het gaat de eigen beurskoers opkopen. Maar dat gaat wel ten kosten van hun belang in Spotify. Jerome Powell mocht voor de laatste keer het rentebeleid van de Fed toelichten, maar toch neemt hij geen afscheid bij de Amerikaanse centrale bank. Hij gaat achter de schermen werken, waardoor hij (voor een laatste keer) president Trump een middelvinger geeft. Te gast: Jean-Paul van Oudheusden van Markets Are Everywhere BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie. Van Musk tot Microsoft en van Ahold tot ASML. Wij vertellen je wat beleggers bezighoudt, wie de markten in beweging zet en wat dat betekent voor jouw beleggingsportefeuille.See omnystudio.com/listener for privacy information.

Started a GLP-1 like Ozempic, Wegovy, Mounjaro, or Zepbound and wondering… is this side effect normal?From nausea and constipation to bloating, fatigue, and feeling full after just a few bites, GLP-1 side effects can feel overwhelming—especially when no one fully explained what to expect.In this episode, Registered Dietitian and GLP-1 expert Gianna breaks down the most common GLP-1 side effects using science-backed, evidence-based information so you can stop guessing and start feeling more confident.We're covering:Why GLP-1 medications cause side effects in the first placeWhat nausea, constipation, bloating, and fatigue usually meanWhen side effects are considered normal vs when they may be a red flagHow to reduce side effects with simple nutrition and lifestyle strategiesThe biggest mistake people make when side effects startWhen it's time to call your healthcare providerWhether you're taking Ozempic, Wegovy, Mounjaro, or Zepbound, learning how to manage side effects properly can make the difference between quitting early and long-term success. ✨ The GLP-1 Circle Membership is open, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey with founding rates starting at $49/month!  Learn more and join here!

A medication that can support weight loss, lower diabetes risk, and protect your heart sounds almost too good to be true. So we get practical about the real decision: not “Do I want a GLP-1?” but “What problem am I trying to solve?” If the goal is better metabolic health, less sleep apnea burden, improved blood pressure, or a long-term plan for obesity as a chronic disease, the conversation changes fast.We break down who should seriously consider GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro, including the common BMI thresholds and the “BMI plus comorbidity” situations. We also talk about the people who have truly done the nutrition and exercise work, lost weight, and watched their body push back with hunger and regain. That's where appetite dysregulation and biology matter, and where GLP-1s can become a powerful tool instead of a moral debate.We also cover who should pause before starting: anyone chasing a quick fix, anyone who hasn't built foundational habits, or anyone who isn't ready for the trade-offs like nausea, fatigue, or constipation. We dig into safety and long-term expectations, why stopping often brings symptoms back, and why easy access through med spas and low-oversight online clinics can be risky, especially with disordered eating history. If you want a calmer, more responsible way to decide, we'll help you map the choice to your story.Subscribe for more practical health conversations, share this with a friend who's on the fence, and leave a review if it helped. What's the biggest question you still have about starting a GLP-1?Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

Weight loss plateaus on GLP-1 therapies such as Wegovy and Zepbound are increasingly understood as a function of biological adaptation rather than patient noncompliance. In this episode I will be discussing CagriSema, an investigational combination therapy expected to launch between late 2026 and early 2027. The treatment combines semaglutide and cagrilintide, targeting complementary mechanisms that regulate appetite and satiety. Clinical trial data indicate weight reduction of up to 22.7%, suggesting improved efficacy relative to existing monotherapies. The development reflects a broader shift toward combination-based treatment models, consistent with approaches used in managing chronic conditions such as diabetes and hypertension.  Listen to the episode for a closer look at what this could mean for treatment pathways and patient outcomes. Episode Highlights: Why plateaus happen and what your body is actually doing What CagriSema is and how its two-ingredient formula works What the REDEFINE trials show including how it stacks up against Tirzepatide Who this medication is most likely to help Why the best plan is still the one that's working for you right now Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

When Penn Holderness described APOE4 as a “ticking time bomb,” it struck a nerve for a lot of people, especially women in midlife who already feel vulnerable about their brain health.Could a GLP-1 medication protect your brain if you carry the APOE4 gene? Amy unpacks the science in plain English and explains why genes are not destiny, why menopause changes the conversation for women, and what research-backed actions you can start taking right now.What to Listen For[00:00] Why Penn Holderness's APOE4 reveal sparked such a big reaction [02:30] What it actually means to carry one or two copies of the APOE4 gene [05:30] Why APOE4 is a genetic predisposition, not a verdict [08:30] The critical difference between APOE4 and the rare genes that directly cause early-onset Alzheimer's [10:30] Why midlife and postmenopausal women may face a different level of APOE4-related risk [14:00] How fear drives people toward quick-fix solutions and why that matters in Alzheimer's prevention [18:00] What the observational GLP-1 research shows and the big caveat most people miss [22:00] What the EVOKE and EVOKE Plus semaglutide trials found in people with early Alzheimer's symptoms [25:30] What hormone therapy can do for sleep and symptom relief — and what it has not been proven to do for dementia prevention [28:30] Why the FINGER study, U.S. POINTER, and modifiable risk-factor research offer the most hopeful path forward [32:30] The free RESTORED guide, the 8 evidence-based lifestyle factors, and Amy's call to take action without panicIf you've been feeling afraid of your genetic risk, this episode is your reminder that APOE4 is not destiny. Amy explains why the most powerful path forward is still grounded in the basics: sleep, movement, metabolic health, stress management, and consistent daily choices. Listen now, subscribe to the show, and grab Amy's free guide so you can start protecting your brain one step at a time.From The EpisodeDownload the free RESTORED ProtocolBook your Breakthrough Roadmap sessionResearch cited in this episode:1. NIA Alzheimer's Disease Genetics Fact Sheet — APOE4 prevalence and risk breakdown https://www.nia.nih.gov/health/alzheimers-causes-and-risk-factors/alzheimers-disease-genetics-fact-sheet2. Altmann A et al. (2014). Sex modifies the APOE-related risk of developing Alzheimer disease. Annals of Neurology. https://pmc.ncbi.nlm.nih.gov/articles/PMC4117990/3. Stanford Medicine (April 2026). Women get Alzheimer's more often than men: Five things the science tells us. https://med.stanford.edu/news/insights/2026/04/women-alzheimers.html4. Alzheimer's Association (2025). Statement on oral semaglutide phase 3 topline data (EVOKE/EVOKE+ trials). https://www.alz.org/news/2025/alzheimers-assRESOURCES:Book a FREE Discovery Call with AmyOrder Amy's book Thoughts Are Habits Too:  Master Your Triggers, Free Yourself From Diet Culture, and Rediscover Joyful Eating.Schedule your Breakthrough Roadmap session with AmyFollow Amy on Instagram @amylangcoaching Follow Amy on Facebook @amylangcoachingSubscribe to Amy's YouTube channel @happyandhealthywithamy

Amanda Tress is the founder and CEO of FASTer Way to Fat Loss, one of the fastest-growing digital fitness and nutrition companies in the U.S. Founded in 2016, FASTer Way delivers a science-backed, sustainable approach combining intermittent fasting, whole-food nutrition, carb cycling, and strategic workouts. Under Amanda's leadership, the brand has grown into a multimillion-dollar company with thousands of certified coaches and over 564,000 clients worldwide.

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Have you ever wondered if weight loss surgery and medication are actually better together — or if choosing one means giving up the other?That question sits at the center of one of the most important — and honestly most misunderstood — conversations happening in metabolic health right now. Most people approach weight loss like it's a multiple choice test: pick surgery, pick medication, pick diet and exercise, and stick with your answer. But the reality is so much more nuanced than that, and the patients who tend to do best are almost never the ones who commit to a single path.Dr. Jessica Cutler is the kind of clinician who genuinely gets that. As both a bariatric surgeon and an obesity medicine specialist at Mercy Medical Center in Baltimore, Maryland, she works on both sides of this care in a way that's pretty uncommon — and incredibly valuable for her patients. She completed her medical degree at the University of Pittsburgh, her general surgery residency at Monmouth Medical Center in New Jersey, and went on to fellowship training in bariatric and minimally invasive surgery at Albany Medical Center in New York. That combination of surgical expertise and medical management in one provider is exactly why she's here — because this conversation needed someone who sees the full picture, not just one piece of it.In this episode:Clearing Up the Misconceptions About Bariatric SurgeryYou Might Qualify for Bariatric Surgery — And Not Even Know ItBariatric Surgery and Type 2 Diabetes: There's Way More to This Story Than Weight LossGLP-1s Changed Everything — Here's How Good Bariatric Care AdaptedThe Best of Both Worlds: Why Surgery and Medication Work Better TogetherWhat Bariatric Surgery Can — and Can't — Do for YouThe Gut Feeling We Can't Ignore: Bariatric Surgery and Your MicrobiomeThe Future of Weight Loss Medicine Is Closer Than You Think — But the Body Is Still Surprising UsAnd if this conversation snippet shifted how weight loss is usually seen — or made things feel a bit clearer — there's a lot more in the full episode. Go give it a listen for the complete discussion and all the details.Connect with Dr. Jessica:Instagram: mercybariatricsWebsite: mdmercy.comConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

What if your struggle with weight loss isn't about willpower at all, but about brain patterns you were born with? In this groundbreaking conversation, Dr. Matthew Weiner and registered dietitian Zoe sit down with neuroscientist Dr. Steve Rondeau, who has conducted over 50,000 EEG brain scans and just released his book Think Like a Brain. Dr. Rondeau reveals that emotional eating, stress eating, and food cravings aren't character flaws—they're measurable brain patterns that show up differently in every person. His research has identified that what we call "stress eating" can manifest in 4,096 different combinations of brain patterns, explaining why the same diet works for one person but fails for another.One of the most exciting revelations is the potential to use brain scans to predict who will respond to GLP-1 medications like Ozempic, Wegovy, and Zepbound before they even take their first dose. Dr. Rondeau discusses the "overwhelmed pattern"—a specific brain biomarker where brain activity slows down under stress, strongly correlated with using food as an escape mechanism. He draws fascinating parallels between GLP-1 medications and psychedelic therapy, explaining how both create a window of opportunity where the usual noise quiets down enough for real behavioral change to happen. The key is using that window effectively with proper integration work.This episode challenges the entire foundation of mental health diagnosis, revealing why the DSM is fundamentally flawed and how brain scan technology can finally match treatments to individual biology rather than broad symptom categories. Dr. Rondeau uses the powerful analogy of a husky in the desert versus the mountains—your brain patterns may be perfectly adapted for certain situations but set you up for failure in others. The conversation explores emerging wearable EEG technology, the inheritance of brain patterns, and the future of truly personalized medicine. Essential listening for anyone who has ever wondered why willpower never seems to be enough.Connect with Dr. Steve Rondeau:Book: Think Like a Brain (thinklikeabrain.com)Available on Amazon, Barnes & Noble, and all major platformsAudiobook coming soonDownload the Pound of Cure App: gololi.ai - AI-powered personalized weight loss planning

Weight loss drugs like Ozempic, Wegovy and Zepbound are widely used for shedding pounds. But what do they mean for your skin and hair? In this episode, host Susan Taylor speaks with Rawaa Almukhtar, MD, a dermatologist at Scripps Clinic, about concerns like "Ozempic face," where rapid weight loss can lead to facial volume loss, sagging skin and a more aged appearance. They also explore hair shedding during weight loss — why it happens, who's most at risk and why it's usually temporary. Plus, simple steps you can take to protect your skin and support healthy hair while on GLP-1 medications.    

Weight loss medication is evolving fast, and in this episode, Lisa Oldson, MD breaks down three major developments you need to know.First, the brand-new Zepbound KwikPen: what it is, how it works, how much it costs, and why it's a game-changer for people using tirzepatide. Next is Wegovy HD at 7.2 mg, the newly FDA-approved higher dose of semaglutide that delivers weight loss results approaching those of bariatric surgery. Importantly, she'll tell you about the most common side effects you need to know about before you ask your doctor about this or other weight loss meds. And finally, a quick update on the oral Wegovy pill, the first-ever GLP-1 medication approved for weight loss that doesn't require an injection.Dr. Oldson covers the efficacy, pricing, availability, and side effects for all three options, and reminds us that excess weight is a chronic medical condition deserving of evidence-based medical treatment, not judgment.Whether you're currently on a weight loss medication, considering one, or just want to stay informed (because EVERYONE is talking about this!), this episode gives you everything you need for a smarter conversation with your doctor and to help you decide if one of these medications might make sense for you. Thanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also, we'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.The Smart Weight Loss Coaching Podcast is for informational purposes only and does not constitute medical advice. Always consult your physician or a qualified healthcare provider before starting, stopping, or changing any medication.

GLP-1 drugs like Ozempic, Wegovy, and Zepbound are prescribed for weight loss, diabetes, and blood-sugar management. But as more people use them, patients are reporting a decrease in cravings for drugs and alcohol. Researchers are now investigating whether GLP-1s might be effective for treating alcohol and drug addiction.  How much do we know? What are the risks? And do these drugs tell us anything new about the biology of addiction? Host Flora Lichtman talks with neuroscientist Joseph Schacht, who is conducting a clinical trial on GLP-1s and alcohol use; and Sarah Carstens, addictions clinical director of Outpatient Services at Penn Medicine's Princeton House Behavioral Health. Guests: Dr. Joseph Schacht is the co-director of the Division of Addiction Science, Prevention, and Treatment at the University of Colorado Anschutz School of Medicine.  Sarah Carstens is the addictions clinical director of Outpatient Services at Penn Medicine's Princeton House Behavioral Health.  Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Send us Fan MailIf you're on a GLP-1 medication or seriously considering one there's a conversation about muscle loss that nobody might be having with you clearly enough. GLP-1 muscle loss is real, it's measurable, and for women over 35, the stakes are higher than for almost anyone else in those clinical trials.Alisha Carlson breaks down what the research actually says about semaglutide, muscle loss, and body composition  without the scare tactics or the blank check. You'll learn why women in perimenopause are uniquely at risk, why the scale is lying to you right now, and the three non-negotiables that determine whether you come out of a GLP-1 cycle leaner and stronger  or just lighter and metabolically worse off.This isn't anti-GLP-1. It's pro-you having the information you actually deserve.WHAT YOU'LL LEARN• What GLP-1 muscle loss actually is — and why it's not just about the medication• Why women over 35 and women in perimenopause face higher risk than almost anyone else in the research• The real percentage of weight lost on semaglutide that can come from lean mass  and what the science says you can do about it• Why resistance training is your most powerful muscle-preservation tool on a GLP-1 and exactly what it needs to look like• How to hit your protein targets even when the medication has killed your appetite• Why tracking strength not just weight  is the body composition move that changes everything• The long-game stakes: what happens to your metabolism, bone density, and health if muscle loss goes unaddressed• The identity shift that separates women who come out of GLP-1 therapy stronger from those who just end up smaller THIS EPISODE IS FOR YOU IF...• You're on a GLP-1 medication like Ozempic, Wegovy, Mounjaro, or Zepbound and want to protect your muscle• You're a woman over 35 considering a GLP-1 and want to know what you're actually signing up for• You're in perimenopause or menopause and noticing your body responding differently to everything• The scale is going down but something feels off — you feel softer, weaker, more depleted• You want a non-diet, sustainable approach to fitness that works with your body, not against it• You're done starting over and ready to build something that actually lastswww.thestrongherway.com/fitandfueled (use code TSW300) to save $300 off your enrollment as a listener

Are GLP-1 medications like Ozempic, Wegovy, or Zepbound right for you, especially as an athlete or active adult? And if you are taking one, how do you lose fat without losing muscle?In this episode of Find Your Edge, Coach Chris Newport, RDN, LDN, CISSN, EP shares what she is seeing in practice with patients using GLP-1 medications and explains how to optimize nutrition for better results.You'll learn:how GLP-1 medications workwhy protein is criticalhow to reduce nausea and constipationwhy fiber, hydration, and nutrient density matterwhat athletes need to know about fueling and performancewhy every person on a GLP-1 should work with a registered dietitianWhether you are considering a GLP-1 or already taking one, this episode will help you make more informed decisions.Learn more or work with us here.Experience the breakthrough when everything finally clicks! Train with expert coaches, fuel with incredible chef-prepared meals, and connect with athletes who love triathlon as much as you do. Join us April 22–26 at beautiful Lake Jocassee for four unforgettable days of swim, bike, run, learning, and community. Spots are almost full: Reserve yours here. Support the show

Every week, there's a new peptide, protocol, or wellness supplement your group chat won't stop talking about. The information is everywhere. The clarity is not."Is This Right for Me?" is a new Commune Podcast series built for exactly that moment. Each episode takes one treatment, therapy, or supplement that keeps flooding your feed and does the one thing the internet rarely does: slows down, looks at the actual evidence, and helps you figure out if it makes sense for you specifically.The first episode tackles GLP-1s. Ozempic, Wegovy, Mounjaro, Zepbound. Jeff breaks down how they work, what the clinical trials actually showed, and what the wellness internet keeps leaving out.This episode covers: What GLP-1s are and how they work in the body The real clinical trial data on semaglutide and tirzepatide What happens to your weight when you stop taking them Muscle loss, gallstones, thyroid risk, and side effects worth knowing Who these drugs make sense for and who they don't The compounding pharmacy crackdown and what it means for you What "natural GLP-1s" actually are and aren't The lifestyle habits that work on the same systems without a prescription This episode was made possible by: Beyond BioHacking: Save $400 on any ticket with code COMMUNE400 at beyondconference.com. Vivobarefoot: Try Vivobarefoot risk-free with a 100-day return guarantee, and get 15% off your order at vivobarefoot.com/commune. Bon Charge: Get 15% off when you order at boncharge.com and use promo code COMMUNE  Sunlighten:  Visit sunlighten.com/commune and use code COMMUNE when you fill out the “Get Pricing' form to save up to $1,600 on your purchase. LMNT: Get a free 8-count Sample Pack of LMNT's most popular drink mix flavors with any purchase at drinklmnt.com/commune.


Not losing weight on a GLP-1 like Ozempic, Wegovy, Mounjaro, or Zepbound? You're not alone—and you're not doing anything wrong.In this episode, Registered Dietitian and GLP-1 expert Gianna breaks down the 5 most common reasons weight loss stalls on GLP-1 medications—and what to do instead.If you feel like your progress is slower than expected, completely stalled, or just confusing… this episode will help you understand what's actually going on in your body.We're covering:Why undereating can slow weight loss on a GLP-1How low protein intake impacts metabolism and muscle lossThe truth about exercise and strength training on GLP-1sThe hidden inconsistency that could be holding you backWhy medication alone isn't enough for long-term resultsWhether you just started your GLP-1 or you've been on one for months, this episode will help you optimize your results, feel better, and build sustainable habits. ✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $49/month. Get first dibs on membership spots here when it launches to the waitlist on 4/28/26: Join the waitlist

A GLP-1 that comes as a simple daily pill and can be taken with or without food sounds like a small change, until you think about real life. We're celebrating two years of Your Checkup and sharing what's surprised us most, from listeners across the country and around the world to the messages that stick with us, like families changing habits after a heart attack or patients bringing notes back after our diabetes episodes.Then we get practical about a timely healthcare headline: orforglipron, the newly approved oral GLP-1 receptor agonist from the same broader medication family as Ozempic and Wegovy. We talk through how GLP-1 medications work on appetite and fullness, what the 72-week clinical trial data actually shows for weight loss, and why “10% of body weight” isn't a cosmetic metric but a medically meaningful shift for cardiometabolic health.We also dig into type 2 diabetes results, including A1C drops and how many people reached key treatment goals, plus the side effects you should expect with dose starts and increases. Finally, we compare the pill's outcomes with injectable options like Wegovy and Zepbound, and we name the real problem many patients face now: access. Cost, insurance coverage, and convenience often decide more than the science does.If you found this helpful, subscribe, share it with a loved one or neighbor, and leave a quick review so more patients can find clear, balanced health education.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

The feud between Novo Nordisk (NYSE:NVO) and Hims & Hers (NYSE:HIMS) has been one of the most dramatic storylines in biotech investing — and it just took a major new turn. Simon Erickson breaks down the four-year saga: from Wegovy's launch and the FDA shortage list, to compounded Semaglutide flooding the market at a fraction of the cost, to patent infringement lawsuits, and finally to the new distribution agreement signed March 9, 2026.We cover the explosive growth potential of GLP-1 weight loss drugs, why the global weight loss drug market could hit $200 billion — double the size of the diabetes market — and what the new Wegovy oral pill means for both companies and investors. We also examine how Eli Lilly (NYSE:LLY) fits into the competitive picture with Zepbound and why its U.S.-based advantage has translated into stronger investor sentiment compared to Novo.Simon shares his investor takeaways: Novo's pricing power is under pressure, the IP battle is far from over, and new CEO Mike Doustdar appears to be taking a harder line on patent enforcement. Meanwhile, Hims & Hers emerges from this feud with greater clarity on what it can and can't sell — and the patent infringement overhang on its stock has been lifted.STOCKS MENTIONED:Novo Nordisk (NYSE:NVO)Hims & Hers (NYSE:HIMS)Eli Lilly (NYSE:LLY)#NovoNordisk #nvo #HimsAndHers #hims #GLP1 #Semaglutide #Wegovy #WeightLossDrugs #Zepbound #EliLilly #InvestingNews #PharmaceuticalStocks #BiotechInvesting #StockMarket #GLP1Stocks #CompoundingSemaglutide #WeightLoss #7investing #Simonerickson

Are you on tirzepatide or semaglutide and struggled with inconsistent weight loss and side effects? On this episode of On The Pen, Dave Knapp and Dr. Ian Ellis dive into the surprising variability of GLP-1 dosing (retatrutide, tirzepatide), even when the weekly dose remains the same. We explore how these subtle dosage changes can lead to frustrating glp-1 side effects and why many individuals eventually give up on their weight loss medication. This new way of thinking about glp-1 dosing could change the obesity medicine game. Referenced Links: http://www.OTPLinks.com00:00 Why most GLP-1 users are never on the same dose twice01:55 Dr. Ian's background: trainer, nutritionist, ER physician04:00 His obsessive relationship with food and body composition07:45 The two impossible choices: obsession or obesity10:12 How medical school destroyed his health10:25 A colleague mentions Ozempic for the first time11:35 His first dose and what real satiety feels like13:00 Why the same dose felt worse every single week15:00 30 lbs lost but the body scan results were horrifying17:30 Why elderly patients are especially at risk on GLP-1s18:35 Patient case: Pat May, 310 lbs, lost over 100 lbs20:45 Semaglutide half-life and dose stacking explained24:50 The therapeutic window and finding your ideal level26:30 Why the dosing protocol was built for trials not people28:00 You are never on the same drug level twice29:00 Patient case: Mary Alice lost 30 lbs below the starting dose32:00 The math behind calculating your precise GLP-1 level35:00 The VoaFit app and making precision dosing scalable36:00 Their patients lost more weight using half the medicine39:30 Why 40 to 70 percent of people quit GLP-1s42:00 Compounding pharmacies and the case for flexible dosing46:00 Using GLP-1 as a thermostat dial for your appetite56:45 Where precision dosing is available now58:30 Beyond GLP-1s: applying this to testosterone and more1:05:30 Why hitting the dose ceiling kills long-term results1:07:00 Dr. Ian's outcome: off GLP-1s completely1:10:00 Fixing a broken one-size-fits-all dosing paradigm1:13:00 How to find Dr. Ian Ellis and VoaFit

We are rebranding from Game-Changing Health to Your GLP-1 Bestie- stay tuned!

It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Metformin may help stem macular degeneration, retatutride moves forward, T1D and demntia link studied, lots of news from ATTD and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  transcript with links:  Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Who's in Vegas? I'll see you there at the Breakthrough T1D summit this weekend. And we have two Club 1921 events for health care providers and patient leaders happening in April – head on over to the website for more. Okay.. our top story this week: XX Metformin may be linked to the slower progression of age-related macular degeneration (AMD). Among people with diabetes who were older than 55, those taking metformin had a 37% lower chance of developing intermediate AMD over a five-year period compared with individuals who were not using the medication. It's one of the leading causes of vision loss in the US and many other western countries. These researchers now say a clinical trial is the next step. https://scitechdaily.com/scientists-discover-surprising-eye-benefit-of-widely-used-diabetes-drug/ XX new study suggests people with type 1 diabetes may be nearly three times as likely to develop dementia compared with people without diabetes. Similarly, people with type 2 diabetes may have roughly twice the risk of dementia compared with those without diabetes. However, the study found an association rather than proof of causation, meaning diabetes was linked to dementia risk but was not shown to directly cause it.   https://www.usnews.com/news/health-news/articles/2026-03-19/both-types-of-diabetes-increase-dementia-risk XX Researchers in Japan say they've developed an insulin pill… in mice.  The study, published in the journal Molecular Pharmaceutics, tested the delivery of oral insulin by building a carrier peptide called DNP-V. This peptide helps to transport insulin through the small intestine, where protein drug absorption is usually poor. The result was a rapid and significant drop in blood glucose, as well as a sustained (longer-term) decrease. The mice's blood sugar was reduced to near-normal levels. Although the researchers are optimistic about the findings translating to larger therapeutic models, they noted that the results in mice do not guarantee the same outcome in humans, and that more research is needed. https://www.foxnews.com/health/needle-free-diabetes-management-could-horizon-study-suggests   XX   Lilly says it's next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients. The drug lowered hemoglobin A1C by an average of 1.7% to 2% across different doses at 40 weeks compared with placebo, and helped patients lose an average of 16.8% of their weight. Retatrutide also met the study's second goal, helping patients at the highest dose lose an average of 16.8% of their weight, or 36.6 pounds, at 40 weeks, when evaluating only patients who stayed on the drug. When analyzing all participants, including those who discontinued treatment, the highest dose of the drug helped patients lose 15.3% of their weight. The company was also "very pleased" with the relatively low discontinuation rates due to side effects, which were up to 5%, he added. But Lilly has yet to file for approval of the drug for obesity or diabetes. The company expects to report findings from seven additional phase three trials on the drug by the end of the year. Still, retatrutide's A1C reduction doesn't appear to be the greatest Lilly has seen within its portfolio: The highest dose of Zepbound lowered the measure by more than 2% at 40 weeks in two separate trials on diabetes patients. Dubbed the "triple G" drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments. That appears to have more potent effects on a person's appetite and satisfaction with food than other treatments.   https://www.cnbc.com/2026/03/19/eli-lillys-obesity-drug-retatrutide-clears-late-stage-diabetes-trial.html XX   The MiniMed Flex gets FDA approval. Thi is a new design from the company formerly known as Medtronic. It's about half the size* of the MiniMed™ 780G pump, no screen – smartphone controlled – and has the SmartGuard™ algorithm with Meal Detection™ technolog. At commercial launch, MiniMed Flex™ will support the company's newest sensor portfolio, including Simplera Sync™ sensor and the Instinct sensor, made by Abbott. MiniMed also announced the MiniMed™ Forward Program, which allows customers who start on the MiniMed™ 780G system to upgrade to the MiniMed Flex™ system for $0. MiniMed Flex™ is cleared for individuals ages 7 and older with type 1 diabetes, and for individuals 18 years and older with insulin-requiring type 2 diabetes. https://www.prnewswire.com/news-releases/minimed-announces-fda-clearance-of-minimed-flex-the-companys-smallest-insulin-pump-featuring-its-first-smartphone-controlled-design-302716864.html   XX Lots of new out of the recent ATTD conference.. some headlines: New study from the UK shows that Ketone Monitoring Could Significantly Reduce DKA Risks in people with type 1 and type 2. This was a study by Abbott which recently submitted a continuous dual glucose-ketone monitor to the FDA for clearance – if approved, it could be available in the U.S. later this year. -- The first modified insulin producing cells are still working 14 months after transplant – without the need for immunosuppressive drugs. This is from Sana which now plans a study of a new therapy.. same gene-editing strategy with lab-grown, stem-cell-derived insulin-producing cells. -- Protein looks like it helps avoid lows during exercise. Both high and low doses of whey protein before exercise were effective, significantly reducing the risk of hypoglycemia by five to 10 times.   Researchers noted that the body's response to protein was rapid (within 20 minutes), which suggests taking it close to the beginning of exercise could be beneficial for preventing hypoglycemia. Though more research is needed, there was also evidence showing protein intake could be beneficial for prolonged fasting and preventing overnight lows. -- More info about type 1 and GLP medications. Researchers at ATTD presented the results of a small, seven-month study assessing the effectiveness of semaglutide for people with type 1 diabetes and obesity. During the trial, 36% of participants taking semaglutide spent more than 70% of their time in range, less than 4% of their time below range, and lost more than 5% of their body weight compared to those not taking semaglutide.   Treatment with semaglutide was also associated with reductions in cholesterol and blood pressure. Based on all of these changes, the researchers calculated that the participants who received semaglutide had significantly reduced their risk of heart disease over the next 10 years.   Other studies show that since 2020, prescriptions of GLP-1 medications have grown exponentially for adults with type 1 diabetes between the ages of 18 and 85. https://diatribe.org/diabetes-research/top-diabetes-news-attd-2026   XX Lots of talk about fully closed loops.. CamDiab unveiled theirs.. called Liberty.. which the company says it's the world's first fully closed loop commercial launch. CamDiab offers the FDA-approved mylife CamAPS FX app for automating insulin delivery in MyLife's (formerly Ypsomed Diabetes Care's) insulin delivery pumps. The mylife CamAPS FX on iOS has full compatibility with leading continuous glucose monitors (CGMs). Those include the FreeStyle Libre 3 and Libre 3 Plus from Abbott and the Dexcom G6 so customers can use their preferred device. https://www.drugdeliverybusiness.com/camdiab-unveils-fully-closed-loop-insulin-feature/ XX Insulet reported data on a fully closed-loop automated insulin delivery system in people with Type 2 diabetes. The 24 people in the trial spent 24% more time in the target blood glucose range using the system than when receiving standard injection therapy. Insulet plans to start a pivotal study this year and aims to launch in 2028. Rival insulin pump manufacturer Tandem is on a similar course. Tandem CEO John Sheridan told investors on an earnings call last month that his team plans to start a pivotal trial this year to support a filing with the Food and Drug Administration in 2027. Medtronic disclosed the start of a pivotal trial of its Vivera fully closed-loop algorithm last month, shortly before spinning off the program as part of the MiniMed initial public offering. The algorithm, which is designed to eliminate carb counting and manual food bolusing, achieved a mean time in range of 73.8% without manual user input in a feasibility study.   https://www.medtechdive.com/news/insulet-posts-clinical-data-on-fully-closed-loop-insulin-delivery-system/814516/ XX Congrats to all honored by the 2026 National Scientific and Health Care Achievement Awards from the American Diabetes Association! Shout out to Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES: 2026 Outstanding Educator in Diabetes Award and to  Korey Hood who receives the Richard Rubin award. Dr. Rubin was a pioneer in behavioral science and committed to keeping the person with diabetes at the center of research and care.

In this essential episode, Dr. Fiona Lovely tackles a massive "information vacuum" surrounding some of the most talked-about medications today. With women aged 50–64 now the primary users of GLP-1 and GIP medications, Dr. Lovely steps in to provide the critical nutritional and physiological guidance that is too often missing from the standard prescription process. She clarifies that for millions of women, these are not "vanity tools" but life-changing medicines for treating chronic diseases like obesity and metabolic dysfunction. Dr. Lovely breaks down the science behind semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), explaining how they mimic natural hormones to regulate hunger and insulin. However, she warns that simply taking the medication without a support plan is "wishful thinking" that can lead to muscle loss and frailty. To help you thrive while on these medications, she introduces her Six Foundational Pillars of Support: Hydration: Why thirst signals disappear alongside appetite and why 2–3 liters of water daily (plus electrolytes) is your best defense against nausea and fatigue. Protein & Muscle Preservation: The non-negotiable need for high protein intake to prevent sarcopenia and the "trade-off" of metabolic health for physical frailty. Resistance Training: Why you must send a signal to your body to keep its muscle through simple, home-based bodyweight exercises or resistance bands. Fiber: Managing the common side effect of constipation by hitting a 25-gram daily target through food first. Nutrient Gaps: Why eating less means absorbing less, and how a "morning stack" of micronutrients and greens can bridge the gap. Mental & Emotional Support: Preparing for the "emotional surfacing" that happens when food is no longer available as a coping mechanism. This episode is a masterclass in health sovereignty, empowering you to move through the menopausal transition stronger and more resilient, rather than depleted.   Thank you to our sponsors for this episode:

"I had enough respect for myself to say: No, I am the smartest person in the room on this one. Just because you label yourself a 'business person' doesn't mean I'm not an even better one. I'm going to burn it all down to build it up stronger." — Dr. Betsy Dovec Is willpower actually the problem, or is it biological warfare? In this episode of Turmeric & Tequila™, Kristen Olson sits down with Dr. Betsy Dovec, the world's #1 female bariatric surgeon and a radical disruptor in the healthcare space. Dr. Dovec shares the gut-wrenching (and inspiring) story of leaving a secure seven-figure hospital job to take out a $12 million loan and build Body by Bariatrics—the country's first fully integrated surgical and wellness facility. We dive deep into: The Truth About GLP-1s: Ozempic, Wegovy, and Zepbound—who they are actually for and the "regain" reality no one talks about. Surgery vs. Medication: Why bariatric care is a preventative, life-saving tool, not a "last resort." The $12M Leap: How Dr. Dovec fought misogyny in healthcare and venture capital to build her own ecosystem. Work-Life Integration: Why "balance" is a myth and how to lead as a high-performing mother and CEO. The Butterfly Effect: The role of spirituality, manifestation, and "the woo" in medical success. Time Stamps: 00:00 – T&T Intro: Kristen Olson kicks off the episode with a mission to question a better way through gracefully disruptive conversations. 00:15 – Sponsor Shout-outs: Big thanks to Colorado Clownfish Swim School and Declan James Watches for supporting the mission. 02:45 – Setting the Stage: Why health and wellness humans need to hear the intersection of GLP-1s and Bariatric Surgery. 04:40 – Meet Dr. Betsy Dovec: From "awkward dork" to the #1 female weight loss surgeon globally. 08:45 – The GLP-1 Breakdown: Understanding the "biological warfare" of food noise and the difference between Ozempic, Wegovy, and Zepbound. 12:14 – Surgery vs. Medication: Why bariatric care is a life-saving tool, not a last resort, and the reality of weight regain. 20:10 – The "White Glove" Approach: How an all-female medical team brings empathy and intuition to high-stakes healthcare. 25:30 – The $12 Million Leap: Quitting the seven-figure hospital job to build Body by Bariatrics from the dirt up. 32:10 – Mission Realized: The emotional reality of the first surgery in her own facility on April 17th, 2025. 36:03 – The Myth of Balance: Dr. Dovec's take on work-life integration for mothers and entrepreneurs. 41:40 – Authenticity Wins: The "Zero Sign-ups" failure that taught Dr. Dovec to ditch the business suit and be herself. 51:00 – Manifestation & Spirituality: Following signs, avoiding bad deals, and the "Butterfly Effect" of success. 53:40 – Defining Success: The "euphoria factor" and hearing the words "Thanks for saving my life." 55:40 – T&T Outro: Kristen closes out the show with a reminder to level up and choose a better way. Cheers!   Dr. Betsy Dovec Dr. Betsy Dovec is a board-certified bariatric surgeon and obesity medicine specialist. After performing over 7,000 surgeries, she founded Body by Bariatrics and the Surgical Institute of Central Florida. She is a pioneer in "value-based care," making life-changing weight loss accessible, affordable, and deeply compassionate. @DrDovec https://bodybybariatrics.com/ @bodybybariatrics   Connect with T&T: IG: @TurmericTequila Facebook: @TurmericAndTequila Website: www.TurmericAndTequila.com Host: Kristen Olson IG: @Madonnashero Tik Tok: @Madonnashero Website: www.KOAlliance.com WATCH HERE MORE LIKE THIS: https://youtu.be/ZCFQSpFoAgI?si=Erg8_2eH8uyEgYZF   https://youtu.be/piCU9JboWuY?si=qLdhFKCGdBzuAeuI https://youtu.be/9Vs2JDzJJXk?si=dpjV31GDqTroUKWH

On The Pen breaks down the latest GLP-1 news, compounded semaglutide updates, tirzepatide controversy, FDA and DDC list developments, Novo Nordisk findings, Eli Lilly B12 tirzepatide concerns, and new oral obesity drug data from Structure Therapeutics. If you follow obesity medicine, weight loss drugs, peptide news, semaglutide, Zepbound, Wegovy, Ozempic, Mounjaro, and patient advocacy, this episode is for you.WAYS TO SUPPORT MY WORK ⬇️http://www.otplinks.com00:00 Massive compound shakeup00:00:43 Why compound users need this00:01:25 Sponsor, Shed obesity care00:02:11 Breaking news changed everything00:02:28 OTP semaglutide exclusive00:03:28 DDC list explained00:04:24 Novo's lab findings00:09:57 302% dose shocker00:13:03 Catalent's contamination mess00:16:33 Lilly's B12 tirzepatide bombshell00:19:34 Is the molecule changing?00:21:46 New oral GLP-1 contender

GLP-1 weight-loss drugs such as Ozempic, Wegovy, Mounjaro and Zepbound are reshaping the treatment of obesity around the world. But even when these medicines are judged “cost-effective”, access often depends on who can afford to pay. In the second episode of our Business Daily series on the global weight-loss economy, Sam Fenwick examines how different countries are funding — or rationing — access to these high-priced injections. In England, the state's National Health System says the drugs offer good value for money, and yet rollout is being phased in slowly because of cost and capacity pressures. In the United Arab Emirates, most patients rely on private insurance or pay out of their own pockets. And in India, where obesity is rising fast, affordability remains a major barrier, although lower-cost generics may soon change that. If these medicines can prevent diabetes, heart attacks and strokes, they might save health systems money in the long run. But right now, governments, insurers and patients are grappling with the same question: Can we afford the weight-loss revolution?Produced and presented by Sam FenwickIf you'd like to get in touch with the team, our email address is businessdaily@bbc.co.ukBusiness Daily is the home of in-depth audio journalism devoted to the world of money and work. From small start-up stories to big corporate takeovers, global economic shifts to trends in technology, we look at the key figures, ideas and events shaping business.Each episode is a 17-minute deep dive into a single topic, featuring expert analysis and the people at the heart of the story.Recent episodes explore the growth in AI, the cost of living, why bond markets are so powerful, China's property bubble, and Gen Z's experience of the current job market.We also feature in-depth interviews with company founders and some of the world's most prominent CEOs. These include Google's Sundar Pichai, Wikipedia founder Jimmy Wales, CEO of Canva Melanie Perkins, and the CEO of Starbucks, Brian Niccol.(Photo: A man gets his waist measured. Credit: Getty Images)

In Part 2, Jen shares her coming out story , her switch to the Trio algorithm , surviving a terrifying solo low , and using Zepbound for insulin resistance. Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Tandem Mobi ** Use code JUICEBOX to save 40% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!